Navigation Links
Clinical Update - Debio 025 in Hepatitis C
Date:4/28/2009

LAUSANNE, Switzerland, April 28 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, presented results from a phase IIa study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect. Revealed at the 44th Annual Meeting of the European Association for the Study of the Liver, in Copenhagen, these findings showed potent antiviral activity.

The phase IIa study investigated the efficacy and safety of Debio 025 in combination with Peg interferon alpha 2a (peg-IFNÿ±2a) and ribavirin in previously null-responder genotype 1 HCV patients. Results demonstrated that Debio 025 at doses of 400 mg (with initial loading) and 800 mg daily for 29 days shows a statistically significant reduction of HCV RNA of respectively -1.96 log (-98.9%) and -2.38 log (-99.5%) when co-administered with Peg-IFN alpha-2a and ribavirin in previous null responders.

"These results in patients who are highly unlikely to respond to re-treatment with an interferon-based regimen, are very important to us, as they confirm that Debio 025 is a potent anti-HCV agent," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We are making it our mission to find a cure for this widely spread and life threatening disease and these findings bring us one step closer to our goal."

About the phase IIa triple therapy study

Debiopharm investigated different dosing regimens of Debio 025 in combination with peg-IFNÿ±2a at 180 micrograms/week and ribavirin at 1000/1200 mg/day in genotype 1 chronic HCV patients that were previously null responders (< 2 log10 HCV-RNA reduction after 12 weeks with peg-IFN(alpha) 2a and ribavirin). Fifty patients were randomised in an open phase IIa study to receive one of five treatment regimens for 29 days. Afterw
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
4. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
5. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
6. Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
7. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
8. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
10. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
11. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... SEATTLE , June 3, 2015 ... acquire Northeast Pharmaceuticals, Inc., bringing together two pharmacy organizations ... with mental illness. Both companies have strong reputations for ... their customers. Genoa ... the behavioral health community and those affiliated with managing ...
(Date:6/3/2015)... , June 3, 2015 Creekridge Capital, ... of its sales channels by adding two new sales ... as a Regional Sales Manager and Stefanie Stark ... Mr. Puma comes to Creekridge with over 20 ... his role at Creekridge, Mr. Puma will be responsible ...
(Date:6/3/2015)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... with AbbVie (NYSE: ABBV ) to develop and ... ENHANZE ™ platform. Under ... an initial $23 million payment, followed by milestone ... up to nine collaboration targets. These payments are ...
Breaking Medicine Technology:Genoa, a QoL Healthcare Company Acquires Northeast Pharmaceuticals, Inc. 2Creekridge Capital Strengthens Sales Team 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3
... 3, 2011 Reportlinker.com announces that a new market ... Probiotics and Prebiotics in Clinical Nutrition ... Introduction Overall sales of clinical nutrition ... US and EU as well as rising incidence of ...
... May 3, 2011 Researchers from the University of ... American Roentgen Ray Society 2011 Annual Meeting ... and reduce radiation exposure for breast cancer patients.   ... systems that can show the location as well as ...
Cached Medicine Technology:Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 2Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 3Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 4Study Shows Same Day PET-Guided Biopsy May Expedite Pre-Operative Work-up For Breast Cancer Patients and Reduce Radiation Exposure 2
(Date:6/3/2015)... Pittsburgh, Pa (PRWEB) June 03, 2015 EMBARGOED ... , Lower Birth Weight Associated with Proximity of Mother’s Home ... women living close to a high density of natural gas ... babies with lower birth weights than women living farther from ... School of Public Health analysis of southwestern Pennsylvania birth ...
(Date:6/3/2015)... 03, 2015 Johnson & Johnson and ... million to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... company allegedly used to market the antipsychotic drug. ... that the Arkansas Attorney General moved to dismiss the ... The Risperdal settlement amounts to just a fraction of ...
(Date:6/3/2015)... Follow us on LinkedIn – ... treatment on account of their better mode of action ... rheumatoid arthritis. The industry is expected to witness a ... drugs to biopharmaceuticals over the coming years. The high ... therapies, and recombinant proteins has attracted industry players to ...
(Date:6/3/2015)... June 03, 2015 Dr. Steven Reisman, a ... Diagnostic Center ( http://www.newyorkcardiac.com ) located in NYC, announced today ... to his practice. In most cases, depending on the level ... day they call, they will be seen by a cardiologist ... as a cardiologist is to ensure that people who have ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 VeoMed ... to expand online and mobile access to premier ... and Maintenance of Certification (MOC) activities. ... VeoMed’s innovative courses to Decker’s extensive lists of ... in purchasing access to VeoMed’s premier online and ...
Breaking Medicine News(10 mins):Health News:Fracking Proximity Associated with Lower Birth Weight 2Health News:Fracking Proximity Associated with Lower Birth Weight 3Health News:Fracking Proximity Associated with Lower Birth Weight 4Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2
... be especially diligent about having routine screening colonoscopies, results ... at Buffalo indicate. , Their findings show that persons ... polyps, known as adenomas, and advanced adenomas than men ... were presented Oct. 19 at a 10:30 a.m. session ...
... Dogs may not only be man,s best friend, they ... children with special needs. According to a new Universit de ... anxiety and enhance the socialization skills of children with Autism ... Psychoneuroendocrinology may be a relatively simple solution to help ...
... is not a foreign sight. But what about a turtle or ... fact, according to Gordon Burghardt, a psychology professor at the University ... monkeys -- need a little play time. "I studied ... never saw anything that I thought was play. Then I had ...
... SEATTLE, Wash.October 18, 2010Researchers at the Allen Institute for ... different activity patterns in the brain in individuals with ... individual differences in the effectiveness and side-effect profiles of ... The study is available in this week,s online early ...
... Oct. 19 (HealthDay News) -- People with depression and ... undergoing surgery, a new study suggests. U.S. researchers ... care units between Oct. 1, 2003 and Sept. 30, ... existing psychiatric condition, including 5,500 (15.5 percent) with depression, ...
... , MONDAY, Oct. 18 (HealthDay News) -- Invasive dental procedures ... heart attack and stroke, researchers say. But the increase ... "I don,t want to downplay this entirely, because we ... just after dental work was done among patients undergoing invasive ...
Cached Medicine News:Health News:Prostate cancer patients are at increased risk of precancerous colon polyps 2Health News:Children's best friend 2Health News:UT professor defines play, discovers even turtles need recess 2Health News:Gene activity in the brain depends on genetic background 2Health News:Depression, Anxiety May Raise Surgery Risks 2Health News:Invasive Dentistry May Raise Short-Term Heart, Stroke Risk 2Health News:Invasive Dentistry May Raise Short-Term Heart, Stroke Risk 3
The TransNeb is a complete medication delivery system in a bag. The TransNeb is a compact, piston compressor providing high-performance while weighing only 11 oz. Versatility. Dependability. Simplici...
... A lightweight (4.2lbs) portable unit with a unique ... It features an oil free aluminum alloy integrated ... Available in a variety of combinations with ... Carrying bag is also available. , ...
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
... GenoID's kit is the first ... HPV for clinical diagnostic use. , ... high-risk and 5 low-risk genotypes of ... of PCR technology but simplifying the ...
Medicine Products: